RxDoctor Payments Data

Neelum Aggarwal

Neurology · Chicago, ILNPI 1154450799

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,492 of the $4,637 with a category attached, or 96.9%. Biogen accounts for 96.9% of it on its own, with 1 other manufacturer making up the rest.

$4,637in general payments, 2019–2025

Across 3 payments — averaging $1545.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$4K
  • Eisai Inc.$146
$944,971in research payments, 2019–2025

Across 82 payments — averaging $11,524 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eisai Inc.$454K
  • Eli Lilly$248K
  • Novartis$230K
  • Janssen Research & Development, LLC$9K
  • Biogen$4K

What the payments were for

  • Consulting fees$4,49297%
  • Food & beverage$1463%

General payments by program year

21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen1$4,492
Eisai Inc.2$146

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,637 in reported general payments places this provider in the 70th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois →

Other neurology in Chicago

See the full list for Illinois →

Where these figures come from

Is this you, or does something look wrong? →